New chalcone derivatives as effective against SARS-CoV-2 agent
Özet
Aims: Flavonoids and related compounds, such as quercetin-based antiviral drug Gene-Eden-VIR/Novirin, inhibit the protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The alkylated chalcones isolated from Angelica keiskei inhibit SARS-CoV proteases. In this study, we aimed to compare the anti-SARS CoV-2 activities of both newly synthesized chalcone derivatives and these two drugs. Methods: Determination of the potent antiviral activity of newly synthesized chalcone derivatives against SARS-CoV-2 by calculating the RT-PCR cycling threshold (Ct) values. Results: Antiviral activities of the compounds varied because of being dose dependent. Compound 6, 7, 9, and 16 were highly effective against SARS-CoV-2 at the concentration of 1.60 µg/mL. Structure-based virtual screening was carried out against the most important druggable SARS-CoV-2 targets, viral RNA-dependent RNA polymerase, to identify putative inhibitors that could facilitate the development of potential anti-coronavirus disease-2019 drug candidates. Conclusions: Computational analyses identified eight compounds inhibiting each target, with binding affinity scores ranging from −4.370 to −2.748 kcal/mol along with their toxicological, ADME, and drug-like properties. © 2021 John Wiley & Sons Ltd
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Duran, Nizami | |
| dc.contributor.author | Polat, M. Fatih | |
| dc.contributor.author | Aktas, Derya Anil | |
| dc.contributor.author | Alagoz, M. Abdullah | |
| dc.contributor.author | Ay, Emrah | |
| dc.contributor.author | Cimen, Funda | |
| dc.contributor.author | Tek, Erhan | |
| dc.contributor.author | Anil, Baris | |
| dc.contributor.author | Burmaoglu, Serdar | |
| dc.contributor.author | Algul, Oztekin | |
| dc.date.accessioned | 2026-10-18T20:28:00.213594397Z | |
| dc.date.available | 2026-10-18T20:28:00.213594397Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Aims: Flavonoids and related compounds, such as quercetin-based antiviral drug Gene-Eden-VIR/Novirin, inhibit the protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The alkylated chalcones isolated from Angelica keiskei inhibit SARS-CoV proteases. In this study, we aimed to compare the anti-SARS CoV-2 activities of both newly synthesized chalcone derivatives and these two drugs. Methods: Determination of the potent antiviral activity of newly synthesized chalcone derivatives against SARS-CoV-2 by calculating the RT-PCR cycling threshold (Ct) values. Results: Antiviral activities of the compounds varied because of being dose dependent. Compound 6, 7, 9, and 16 were highly effective against SARS-CoV-2 at the concentration of 1.60 µg/mL. Structure-based virtual screening was carried out against the most important druggable SARS-CoV-2 targets, viral RNA-dependent RNA polymerase, to identify putative inhibitors that could facilitate the development of potential anti-coronavirus disease-2019 drug candidates. Conclusions: Computational analyses identified eight compounds inhibiting each target, with binding affinity scores ranging from −4.370 to −2.748 kcal/mol along with their toxicological, ADME, and drug-like properties. © 2021 John Wiley & Sons Ltd | |
| dc.identifier.doi | 10.1111/ijcp.14846 | |
| dc.identifier.eissn | 1742-1241 | |
| dc.identifier.issn | 1368-5031 | |
| dc.identifier.issue | 12 | |
| dc.identifier.pmcid | PMC8646589 | |
| dc.identifier.pmid | 34519118 | |
| dc.identifier.scopus | 2-s2.0-85115626984 | |
| dc.identifier.startpage | e14846 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/13162 | |
| dc.identifier.volume | 75 | |
| dc.identifier.wos | WOS:000698956100001 | |
| dc.language.iso | en | |
| dc.publisher | John Wiley and Sons Inc | |
| dc.relation.ispartof | International Journal of Clinical Practice | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Antiviral Agents | |
| dc.subject | Chalcone | |
| dc.subject | Chalcones | |
| dc.subject | COVID-19 | |
| dc.subject | Humans | |
| dc.subject | SARS-CoV-2 | |
| dc.subject | 1 (2,5 difluorophenyl) 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one | |
| dc.subject | 1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl) 3 (2,5 difluorophenyl)prop 2 en 1 one | |
| dc.subject | 1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl) 3 (3,5 difluorophenyl)prop 2 en 1 one | |
| dc.subject | 1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl) 3 [2 fluoro 5 ( trifluoromethyl)phenyl]prop 2 en 1 one | |
| dc.subject | 1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl) 3(2,4,5 trifluorophenyl)propprop 2 en 1 one | |
| dc.subject | 1 (3 bromo 2 hydroxy 4,6 dimethoxyphenyl)ethan 1 one | |
| dc.subject | 1 (3,5 difluorophenyl) 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one | |
| dc.subject | 1 [2 fluoro 5 (trifluoromethyl)phenyl] 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one | |
| dc.subject | 1 [3,5 bis(trifluoromethyl)phenyl] 3 (2,4,6 trimethoxyphenyl)prop 2 en 1 one | |
| dc.subject | anti-SARS-CoV-2 agent | |
| dc.subject | chalcone derivative | |
| dc.subject | unclassified drug | |
| dc.subject | virus RNA | |
| dc.subject | antivirus agent | |
| dc.subject | antiviral activity | |
| dc.subject | Article | |
| dc.subject | binding affinity | |
| dc.subject | carbon nuclear magnetic resonance | |
| dc.subject | controlled study | |
| dc.subject | dose response | |
| dc.subject | drug efficacy | |
| dc.subject | drug isolation | |
| dc.subject | drug potency | |
| dc.subject | drug structure | |
| dc.title | New chalcone derivatives as effective against SARS-CoV-2 agent | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 37 | |
| rdl.citation.wos | 31 | |
| rdl.department | Department of Pharmaceutical Basic Sciences, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, Turkey. | Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, Turkey. | |
| rdl.oa.status | green | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
